Imidazenil prevention of alprazolam-induced acquisition deficit in patas monkeys is devoid of tolerance.
The partial allosteric modulators (PAMs) of gamma-aminobutyric acid-gated Cl(-) current intensities at gamma-aminobutyric acid type A receptors have high affinity but low intrinsic efficacy on benzodiazepine recognition sites. Unlike the full allosteric modulators (FAM), like alprazolam, triazolam, and diazepam, PAMs are virtually devoid of unwanted side effects, including tolerance. Imidazenil (IMD) is a PAM that elicits potent anxiolytic and anticonvulsant actions in rodents and nonhuman primates and retains its anticonvulsant and anxiolytic effects, even in rodents that are tolerant to FAMs. IMD antagonizes the side effects of FAMs in rodents and nonhuman primates. Using patas monkeys and a multiple schedule with repeated acquisition and performance of chain responses, we report that IMD administration for 17 days antagonized without showing tolerance ALP-induced disruption of acquisition.
Auta
J
J
Department of Psychiatry, The Psychiatric Institute, University of Illinois, M/C 912, 1601 West Taylor Street, Chicago, IL 60612, USA.
Guidotti
A
A
Costa
E
E
D000525:Alprazolam / Q000494:pharmacology*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D004901:Erythrocebus patas; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D013647:Task Performance and Analysis
D014151:Anti-Anxiety Agents; D018757:GABA Modulators; D007093:Imidazoles; D001569:Benzodiazepines; C082661:imidazenil; D000525:Alprazolam